Kitov Product Pipeline The Kitov pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates that maintain advantages over current therapies or address unmet medical needs. The pipeline consists of two therapeutic candidates:
- Consensi™ – a fixed-dose combination of two approved drug products that is indicated for the treatment of osteoarthritis pain and hypertension simultaneously. Under the prescription Drug User Fee Act (PDUFA), the U.S. Food & Drug Administration (FDA) approved Consensi™ for marketing in the U.S.A. on May 31, 2018.
- NT-219 – a first-in-class small molecule designed to overcome cancer drug resistance